Director received an award of 65K OVID derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Feb 26, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Mar 2, 2026
DirectorGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001202098-26-000002
- Filed / recorded
Added to OQROOct 7, 2026, 5:52 AM UTC Data qualityVerified: identifiers matched exactly IssuerOvid Therapeutics Inc. Reporting personStelios Papadopoulos SecurityEmployee Stock Option (Right to Buy) TableDerivative (Table II) Transaction dateFeb 26, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.